204 related articles for article (PubMed ID: 16417448)
1. Novel treatment with rituximab of oropharyngeal posttransplant lymphoproliferative disorder after heart transplantation.
Kaczmarek I; Beiras-Fernandez A; Sadoni S; Bengel D; Deutsch MA; Meiser B; Reichart B
Exp Clin Transplant; 2005 Dec; 3(2):381-4. PubMed ID: 16417448
[TBL] [Abstract][Full Text] [Related]
2. Posttransplant lymphoproliferative disorder.
Everly MJ; Bloom RD; Tsai DE; Trofe J
Ann Pharmacother; 2007 Nov; 41(11):1850-8. PubMed ID: 17940127
[TBL] [Abstract][Full Text] [Related]
3. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission.
Knoop C; Kentos A; Remmelink M; Garbar C; Goldman S; Feremans W; Estenne M
Clin Transplant; 2006; 20(2):179-87. PubMed ID: 16640524
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab.
Garceau P; Couture C; Cantin B; Bernier V; Sénéchal M
J Heart Lung Transplant; 2008 Aug; 27(8):928-31. PubMed ID: 18656811
[TBL] [Abstract][Full Text] [Related]
5. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
[TBL] [Abstract][Full Text] [Related]
6. Brain tumor as an unusual presentation of posttransplant lymphoproliferative disorder.
Azarpira N; Torabineghad S; Rakei M
Exp Clin Transplant; 2009 Mar; 7(1):58-61. PubMed ID: 19364315
[TBL] [Abstract][Full Text] [Related]
7. Tumor lysis syndrome occurring after the administration of rituximab for posttransplant lymphoproliferative disorder.
Francescone SA; Murphy B; Fallon JT; Hammond K; Pinney S
Transplant Proc; 2009 Jun; 41(5):1946-8. PubMed ID: 19545762
[TBL] [Abstract][Full Text] [Related]
8. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation.
Lee JJ; Lam MS; Rosenberg A
Ann Pharmacother; 2007 Oct; 41(10):1648-59. PubMed ID: 17848421
[TBL] [Abstract][Full Text] [Related]
9. Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus.
Kaposztas Z; Etheridge WB; Kahan BD
Transplant Proc; 2008 Jun; 40(5):1744-6. PubMed ID: 18589184
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment.
Garcia VD; Bonamigo Filho JL; Neumann J; Fogliatto L; Geiger AM; Garcia CD; Barros V; Keitel E; Bittar AE; Ferrera des Santos A; Roithmann S
Transpl Int; 2003 Mar; 16(3):202-6. PubMed ID: 12664217
[TBL] [Abstract][Full Text] [Related]
11. Rapid response to rituximab in a pediatric liver transplant recipient with post-transplant lymphoproliferative disease and maintenance with sirolimus monotherapy.
Al-Akash SI; Al Makadma AS; Al Omari MG
Pediatr Transplant; 2005 Apr; 9(2):249-53. PubMed ID: 15787802
[TBL] [Abstract][Full Text] [Related]
12. Usefulness and limitations of rituximab in managing patients with lymphoproliferative disorder after heart transplantation.
Senechal M; Demers S; Cantin B; Bourgault C; Leblanc MH; Morin J; Couture C
Exp Clin Transplant; 2012 Oct; 10(5):513-8. PubMed ID: 22747415
[TBL] [Abstract][Full Text] [Related]
13. Post-transplant EBV-related lymphoproliferative disorder complicating umbilical cord blood transplantation in patients of adrenoleukodystrophy.
Cheng FW; Lee V; To KF; Chan KC; Shing MK; Li CK
Pediatr Blood Cancer; 2009 Dec; 53(7):1329-31. PubMed ID: 19591223
[TBL] [Abstract][Full Text] [Related]
14. Long-term maintenance therapy for post-cardiac transplant monoclonal lymphoproliferative disorder: caveat mammalian target of rapamycin.
Khalpey Z; Miller DV; Schmitto JD; Kushwaha SS
Transplant Proc; 2011 Jun; 43(5):1893-9. PubMed ID: 21693296
[TBL] [Abstract][Full Text] [Related]
15. Aggressive posttransplant lymphoproliferative disease in a renal transplant patient treated with alemtuzumab.
Muzaffar M; Taj A; Ratnam S
Am J Ther; 2010; 17(6):e230-3. PubMed ID: 19918163
[TBL] [Abstract][Full Text] [Related]
16. [Lymphoproliferative syndromes after cardiac transplantation and treatment with cyclosporine. Report of 4 cases].
Guerci AP; Burtin P; Mattei S; Lederlin P
Ann Med Interne (Paris); 1992; 143(3):155-9. PubMed ID: 1524349
[TBL] [Abstract][Full Text] [Related]
17. Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation.
Cornejo A; Bohnenblust M; Harris C; Abrahamian GA
Cancer Chemother Pharmacol; 2009 Sep; 64(4):857-60. PubMed ID: 19588139
[TBL] [Abstract][Full Text] [Related]
18. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease.
González-Barca E; Domingo-Domenech E; Capote FJ; Gómez-Codina J; Salar A; Bailen A; Ribera JM; López A; Briones J; Muñoz A; Encuentra M; de Sevilla AF; ; ;
Haematologica; 2007 Nov; 92(11):1489-94. PubMed ID: 18024397
[TBL] [Abstract][Full Text] [Related]
19. Post-transplant lymphoproliferative disease in children following solid organ transplant and rituximab--the final answer?
Gross TG
Pediatr Transplant; 2007 Sep; 11(6):575-7. PubMed ID: 17663676
[No Abstract] [Full Text] [Related]
20. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
Oertel S; Trappe RU; Zeidler K; Babel N; Reinke P; Hummel M; Jonas S; Papp-Vary M; Subklewe M; Dörken B; Riess H; Gärtner B
Ann Hematol; 2006 Jul; 85(7):478-84. PubMed ID: 16586109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
